Literature DB >> 10786716

Amyloid beta peptide impaired carbachol but not glutamate-mediated phosphoinositide pathways in cultured rat cortical neurons.

H M Huang1, H C Ou, S J Hsieh.   

Abstract

Signal transduction systems, including cholinergic pathways, which are likely to be of pathophysiological significance are altered in Alzheimer's disease (AD). Muscarinic cholinergic receptors are linked to the hydrolysis of phosphoinositide, involving the production of inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] and the mobilization of cytosolic free calcium concentrations ([Ca2+]i). Effects of amyloid peptide (A(beta)) on these signals prior to neuronal degeneration were examined in cultured rat cortical cells. A(beta) increased the release of lactate dehydrogenase (LDH) in a concentration-dependent manner, however, it was blocked by B27 supplement. Prolonged exposure to a sublethal dose of A(beta) 25-35 or 1-42 disrupted carbachol-mediated release of Ins(1,4,5)P3 and [Ca2+]i, which was inhibited in media supplemented with B27 or the antioxidant vitamin E. In order to determine the specificity of the effect of A(beta), various agonists glutamate or KCl but not bradykinin which utilize the phosphoinositide cascade were investigated. Our results indicated that A(beta) did not affect the stimulation of glutamate or KCl-mediated production of Ins(1,4,5)P3 or cause elevation in [Ca2+]i. Furthermore, metabotropic agonist trans-1-amino-cyclopentane-1,3,-dicarboxylate (ACPD) elevated calcium level was not inhibited by A(beta) pre-treatment. Taken together, the results demonstrate that a sublethal dose of A(beta) selectively impaired cholinergic receptor-mediated signal transduction pathways, and antioxidant or B27 supplement attenuated this effect of A(beta). Alterations of cholinergic signaling by prolonged exposure to A(beta) could be involved in cortical neurodegeneration that occurs in AD. Because functional loss of cholinergic pathways is an important aspect of AD, the differences in susceptibility of these two types of receptors prior to other signs of A(beta) action is important and requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786716     DOI: 10.1023/a:1007592007956

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  55 in total

1.  Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo.

Authors:  E Masliah; C E Westland; E M Rockenstein; C R Abraham; M Mallory; I Veinberg; E Sheldon; L Mucke
Journal:  Neuroscience       Date:  1997-05       Impact factor: 3.590

2.  Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons.

Authors:  J F Kelly; K Furukawa; S W Barger; M R Rengen; R J Mark; E M Blanc; G S Roth; M P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients.

Authors:  D Storga; K Vrecko; J G Birkmayer; G Reibnegger
Journal:  Neurosci Lett       Date:  1996-01-12       Impact factor: 3.046

4.  Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity.

Authors:  N Kitaguchi; Y Takahashi; Y Tokushima; S Shiojiri; H Ito
Journal:  Nature       Date:  1988-02-11       Impact factor: 49.962

5.  Effect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures.

Authors:  P S Puttfarcken; A M Manelli; M T Falduto; G S Getz; M J LaDu
Journal:  J Neurochem       Date:  1997-02       Impact factor: 5.372

6.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor.

Authors:  J D Buxbaum; M Oishi; H I Chen; R Pinkas-Kramarski; E A Jaffe; S E Gandy; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

7.  Physiological levels of beta-amyloid increase tyrosine phosphorylation and cytosolic calcium.

Authors:  Y Q Luo; N Hirashima; Y H Li; D L Alkon; T Sunderland; R Etcheberrigaray; B Wolozin
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

Review 8.  Neuroreceptor changes in Alzheimer disease.

Authors:  A Nordberg
Journal:  Cerebrovasc Brain Metab Rev       Date:  1992

9.  Vitamin E protects nerve cells from amyloid beta protein toxicity.

Authors:  C Behl; J Davis; G M Cole; D Schubert
Journal:  Biochem Biophys Res Commun       Date:  1992-07-31       Impact factor: 3.575

Review 10.  The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease.

Authors:  J P Blass; G E Gibson
Journal:  Rev Neurol (Paris)       Date:  1991       Impact factor: 2.607

View more
  5 in total

1.  Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity.

Authors:  A Law; S Gauthier; R Quirion
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 2.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.

Authors:  Satyabrata Kar; Stephen P M Slowikowski; David Westaway; Howard T J Mount
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

Review 3.  Molecular rationale for the pharmacological treatment of Alzheimer's disease.

Authors:  Martina Zimmermann; Fabrizio Gardoni; Monica Di Luca
Journal:  Drugs Aging       Date:  2005       Impact factor: 4.271

4.  Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease.

Authors:  Magdalena Elisabeth Siwek; Ralf Müller; Christina Henseler; Astrid Trog; Andreas Lundt; Carola Wormuth; Karl Broich; Dan Ehninger; Marco Weiergräber; Anna Papazoglou
Journal:  Neural Plast       Date:  2015-04-02       Impact factor: 3.599

5.  Amyloid Beta peptides differentially affect hippocampal theta rhythms in vitro.

Authors:  Armando I Gutiérrez-Lerma; Benito Ordaz; Fernando Peña-Ortega
Journal:  Int J Pept       Date:  2013-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.